OncoDrex is developing targeted therapies for hard to treat metastatic cancers such triple negative breast cancer (TNBC). The company has identified unique molecular signatures in metastatic TNBC and is developing small molecules as drug candidates against this signature. This unique molecular signature also has allowed the company to develop a companion diagnostic to select responders to its TNBC drug candidate, an attractive component in a drug development program.
Hormone receptor positive breast cancer is most common type of breast cancer with an impressive overall survival due to targeted endocrine therapy. However, the recurrence is common due to endocrine therapy resistance. There are no standard guidelines for endocrine therapy period (5 years vs 10 years). Oncodrex’s Predictive Diagnostics remove the fear of “WHAT IF COMES BACK” by predicting the likelihood of HR+ breast cancer recurrence. The IHC based predictive test could easily be adopted by including in the primary tumor receptor status panel
Colorectal cancer (CRC) is one of the most preventable cancers with screening and yet still is the third leading cause of cancer death worldwide. Given the high impact of CRC, there is an urgent need for a convenient, accurate and cost-effective screening test that could triage patients for more intensive procedures such as colonoscopy. This would improve patient compliance and clinical outcomes with resulting significant impact on both population health and health care costs. A blood-based screening test is an attractive alternative to increase compliance. Additionally, if an improved screening test could also detect pre-malignant polyps, this would provide an extraordinary opportunity not only to identify early, but also to actually prevent cancer since patients with positive screening tests for pre-malignant lesions can be followed up with colonoscopy to remove these lesions before developing cancer. Oncodrex has developed a simple blood-based test for the screening and early detection of precancerous and cancerous lesions of colon and rectum.